Positions
- Assistant Professor
-
Department of Pathology & Immunology
Center for Drug Discovery
Baylor College of Medicine
- Assistant Professor
-
Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology
Baylor College of Medicine
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Addresses
- Jan and Dan Duncan Neurological Research Institute Building (Office)
-
Room: N.0670.05 (6th Floor)
Houston, TX 77030
United States
Education
- PhD from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
- 07/2015 - Shanghai, China
- Postdoctoral Training at Baylor College of Medicine
- 07/2018 - Houston, Texas United States
- Postdoctoral Training at Dana-Farber Cancer Institute, Harvard Medical School
- 01/2022 - Boston, Massachusetts United States
Professional Interests
- Chemical Biology
- Medicinal Chemistry
Websites
Selected Publications
- Miao Q, Kadam VD, Mukherjee A, Tan Z, Teng M.* "Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches." J. Med. Chem. 2023 Sep;66(19):13369-13383. Pubmed PMID: 37738232
- Teng M,* Gray NS.* "The rise of degrader drugs." Cell Chem. Biol. 2023 Aug;30(8):864-878. Pubmed PMID: 37494935
- Teng M, Jiang J, et al "Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader." Angew. Chem. Int. Ed. Engl. 2023 Apr;62(18):e202302364. Pubmed PMID: 36898968
- Teng M,* et al "The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush." J. Med. Chem. 2022 Oct;65(21):14289-14304. Pubmed PMID: 36265019
- Teng M, et al "The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug." J. Med. Chem. 2022 May;65(11):7581-7594. Pubmed PMID: 35609336
- Teng M, Lu W, et al "Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216." J. Med. Chem. 2022 Jan;65(1):747-756. Pubmed PMID: 34965125
- Teng M, Jiang J, Ficarro SB, et al "Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development." ACS Med. Chem. Lett. 2021 Jul;12(8):1302-1307. Pubmed PMID: 34413960
- Teng M, et al "Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface." ACS Med. Chem. Lett. 2020 Apr;11(6):1269-1273. Pubmed PMID: 32551010
- Teng M, Jiang J, et al "Development of CDK2 and CDK5 Dual Degrader TMX-2172." Angew. Chem. Int. Ed. Engl. 2020 Aug;59(33):13865-13870. Pubmed PMID: 32415712
- Teng M, et al "Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia." Bioorg. Med. Chem. Lett. 2017 Nov;27(22):4979-4984. Pubmed PMID: 29037948
- Teng M, et al "Total synthesis of the monoterpenoid indole alkaloid (±)-aspidophylline A." Angew. Chem. Int. Ed. Engl. 2014 Jan;53(7):1814-1817. Pubmed PMID: 24481917
Funding
- First-Time Tenure-Track Faculty Recruitment Award - #RR220012
- $2,000,000.00 (12/01/2021 - 11/30/2026) Grant funding from the Cancer Prevention and Research Institute of Texas
Log In to edit your profile
